As first-line treatment for metastatic breast cancer in HER2-positive patients, trastuzumab (Herceptin) can be given as a single agent, followed by docetaxel (Taxotere) upon progression, without compromising time to recurrence and providing a better toxicity profile
Greater utilization of dynamic contrast-enhanced MRI at the University of California, San Diego, over a 6-year period helped improve surgery planning for tough breast cancer cases without hiking mastectomy rates
Sequential docetaxel (Taxotere)-based chemotherapy did not lead to better outcomes than standard anthracycline-based chemotherapy among women with resected breast cancer in the Taxotere as Adjuvant Chemotherapy Trial (TACT), the largest primary adjuvant trial of taxanes to date.
If therapeutic agents are documented to be more effective than standard therapies in the advanced breast cancer setting, they will also be effective in the adjuvant setting. This renders randomized phase III adjuvant trials unnecessary in many cases, and means that undue delays in moving new agents up-front are costing lives
Preliminary survival data are encouraging for the triple-drug combination of trastuzumab (Herceptin), docetaxel (Taxotere), and capecitabine (Xeloda) as first-line therapy for locally advanced or metastatic breast cancer
Studies show that thousands of women may be receiving the wrong breast cancer treatment because of faulty laboratory reports. More disturbing, this trend was identified years ago. A 2006 study led by Genentech found 14% to 16% of HER2 tests were false positive and 18% to 23% were false negative.
The FDA has approved a new indication for Genentech's Herceptin (trastuzumab) as a single agent for the adjuvant treatment of HER2-overexpressing, node-negative (ER/PR-negative or with one high-risk feature) or node-positive breast cancer, following multimodality anthracycline-based therapy.
Ixabepilone is indicated in combination with capecitabine(Xeloda) for the treatment of patients with metastatic orlocally advanced breast cancer resistant to prior anthracyclineand paclitaxel treatment (or for whom this treatmentis contraindicated).
MRI has outrun other modalities in a screening trial involving high-risk women. Such research helps justify an estimated $1.4 billion a year in direct costs for the United States if new American Cancer Society guidelines
The combination of capecitabine (Xeloda) and ixabepilone (Ixempra) appears to be robust in patients with the so-called triple-negative breast cancer phenotype
By a 5-4 vote, the Oncology Drugs Advisory Committee failed to recommend that FDA approve Avastin (bevacizumab, Genentech) in combination with paclitaxel as a first-line treatment for locally recurrent or metastatic, HER2-negative breast cancer.
Breast MRI identifies mammographically occult secondary tumors in about 6% of women with early-stage breast cancer who would otherwise qualify for partial breast irradiation
In the neoadju-vant treatment of early breast cancer, fulvestrant (Faslodex) 500 mg effected a greater reduction in biomarkers of proliferation and produced more responses than the standard 250 mg dose
African-American women with early-stage breast cancer are more likely than their Caucasian counterparts to experience a relapse after breast-conserving therapy, but the absolute difference in risk is small
Studies presented at the 2007 San Antonio Breast Cancer Symposium raise new questions about the role of anthracycline-based regimens as adjuvant therapy in early breast cancer, suggesting that these regimens may be appropriate only for a small subset of patients.
Partial breast irradiation (PBI) with concurrent chemotherapy is feasible and is associated with an acceptable rate of toxicity
A cutting-edge prognostic tool called MammaPrint, developed by Agendia, a laboratory located in The Netherlands, uses molecular technology to predict whether breast cancer will metastasize, helping clinicians make more accurate management decisions for their patients.
Use of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy to treat resected early-stage breast cancer is associated with good early outcomes in terms of local control, adverse effects, and cosmesis
Anastrozole (Arimidex) is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers.
Strides made in the treatment of metastatic breast cancer (MBC) appear to prolong survival in some settings, but the cost in terms of quality of life (QOL) remains a concern. The previous four E-Updates in this series on metastatic breast cancer have focused on the various treatment options, including chemotherapy, anti-HER2 targeted therapy, antiangiogenic therapy, and hormonal therapy. In this E-Update, we turn to the role of supportive measures in the treatment of cancer, specifically as these measures relate to quality of life. These measures include the use of erythropoiesis-stimulating agents (ESA) and bisphosphonates, management of fatigue and pain, and psychological care.
The massive American College of Radiology Imaging Network 6666 trial shows that adding ultrasound to the initial screening protocol for high-risk women could help detect 30% more cancers. The cost, however, could be many more needless biopsies of benign lesions.
Adding a radiation therapy boost to the lumpectomy site after lumpectomy with whole-breast radiation therapy reduces the risk of local recurrence, particularly among breast cancer patients with high-risk features, including positive margins.
Photography exhibit features breast and ovarian cancer patients and families
A new model for calculating invasive breast cancer risk, called the CARE model, has been found to give better estimates of the number of breast cancers that would develop in African-American women age 50 to 79 years than an earlier model known as BCRAT (Breast Cancer Risk Assessment Tool), which was based primarily on data from white women
The decision to treat metastatic breast cancer with combination or single-agent chemotherapy may depend on the patient's and the clinician's perception and definition of the goals of such therapy, according to speakers at the 3rd Annual Oncology Congress.
